Results 71 to 80 of about 1,115 (165)
Pharmaceutical Cocrystal and Salts of Norfloxacin
, 2016 The aim of this study was to investigate the structural and pharmaceutical properties of norfloxacin (a poorly soluble antibacterial drug), its cocrystal, and salts. Norfloxacin in the anhydrous form (form A, 1) was crystallized.
Dan Boström (2476249) +2 more
core +1 more source
Communications in Science and Technology, 2020 Mefenamic acid is an analgesic non-steroidal anti-inflammatory drug (NSAID) that is categorized as Biopharmaceutical Classification System (BCS) class II drug. Cocrystallization of mefenamic acid (MFA) with nicotinamide (NIC) has been reported to enhance
Ari Wahyudi +2 more
doaj +1 more source
ChemMedChem, Volume 21, Issue 10, 27 May 2026.We developed a targeted covalent inhibitor for the p300/CBP‐associated factor (PCAF) bromodomain. Our lead molecule, 10, labeled a unique lysine residue in the PCAF bromodomain, demonstrated potent inhibition in biophysical/biochemical assays, and engaged the PCAF bromodomain in cells.
Richard R. Ede +9 more
wiley +1 more source
Mechanochemically Driven Synthesis of Anticancer Cocrystals: A Case Study of Lenalidomide
Chemistry–Methods, Volume 6, Issue 5, May 2026.The combination of crystal engineering and mechanochemical approaches is a powerful strategy for the rational screen and development of new solid forms of active pharmaceutical ingredients (API). New supramolecular patterns formed between an API and a coformer allow the adjustment of physicochemical properties of drugs.
Ana C. S. Carvalho +15 more
wiley +1 more source
Pharmaceutical Cocrystals: An Overview
Asian Journal of Pharmaceutical Research and DevelopmentPoor aqueous solubility and low oral bioavailability of an active pharmaceutical ingredient are the major constraints during the development of new product. Various approaches have been used for enhancement of solubility of poorly aqueous soluble drugs, but success of these approaches depends on physical and chemical nature of molecules being developed.
null Jagdish Kumar Rawal +1 more
openaire +1 more source
, 2018 Pharmaceutical cocrystals have attracted increasing attention over the past decade as an alternative way to modify the physicochemical properties and hence improve the bioavailability of a drug, without sacrificing thermodynamic stability.
Tao Yu (176965) +5 more
core +1 more source
The Cocrystal of Ubiquinol: Improved Stability and Bioavailability
, 2023 Coenzyme Q10 (CoQ10) exists in two forms, an oxidized form and a reduced form. Ubiquinol is the fully reduced form of CoQ10. Compared to the oxidized form, ubiquinol has a much higher biological absorption and better therapeutic effect.
Yinghong Yang +6 more
core +1 more source
MedComm, Volume 7, Issue 5, May 2026.Novel phenylalanine derivatives were identified as HIV‐1 capsid inhibitors. IC‐2i showed significant anti‐HIV‐1 activity at picomolar concentrations. ABSTRACT The HIV‐1 capsid (CA) is a validated antiviral target that plays critical roles in both the early and late stages of the viral life cycle.
Xujie Zhang +18 more
wiley +1 more source
Pharmaceutical cocrystals: from serendipity to design to application [PDF]
Drug Discovery Today, 2019 The field of pharmaceutical cocrystals has reached a tipping point, particularly because cocrystals can improve the physicochemical properties of drugs without compromising their therapeutic benefit. Accounts of cocrystal investigations in the literature started in earnest in 2003 and patent applications soon followed.
Oisin N. Kavanagh +3 more
openaire +3 more sources
Clinical and Translational Science, Volume 19, Issue 5, May 2026.ABSTRACT Genetic variants in drug transporter genes shape the interindividual variability in drug response. However, their functional interpretation has remained limited due to the substrate dependence of variant effects. Existing predictors are substrate‐agnostic and cannot capture how a single amino acid change differentially affects transport across
Yoomi Park +4 more
wiley +1 more source